CMR International thomsonreuters.com

Animal Toxicity Studies — Their Relevance for Man

Author(s): C E Lumley & S R Walker (Eds)
Publisher: Quay Publishing, Lancaster, England
Category: Toxicology

Assessment of Pharmaceuticals for Potential Human Carcinogenic Risk

Author(s): C E Lumley & J A N McAuslane (Eds)
Publisher: CMR International Workshop Review
Category: Toxicology

Building Quality Measures into the Regulatory Review Process: Assessing the Needs of Industry and Regulators

Author(s): C Hynes, J A N McAuslane & S R Walker (Eds)
Publisher: CMR International Workshop Review
Category: Regulatory

Computerized Control Animal Pathology Databases: Will They be Used?

Author(s): J A N McAuslane, C Parkinson & C E Lumley (Eds)
Publisher: CMR Publication
Category: Toxicology

Creating the Research Environment for Drug Discovery

Author(s): S R Walker (Ed)
Publisher: Quay Publishing, Lancaster, England
Category: R&D

Current Issues in Reproductive and Developmental Toxicology - Can an International Guideline be Achieved?

Author(s): C E Lumley & S R Walker (Eds)
Publisher: Quay Publishing, Lancaster, England
Category: Toxicology

Current Strategies and Future Prospects in Pharmaceutical Outsourcing

Author(s): R G Hughes & C E Lumley (Eds)
Publisher: Technomark Consulting Services
Category: Outsourcing

Improving the Regulatory Review Process - Industry and Regulatory Initiatives

Author(s): C E Lumley & S R Walker (Eds)
Publisher: Kluwer Academic Publishers, The Netherlands
Category: Regulatory

Improving the Regulatory Review Process: Assessing Performance and Setting Targets

Author(s):J A N McAuslane & S R Walker (Eds)
Publisher: Kluwer Academic Publishers, The Netherlands
Category: Regulatory

International Medicines Regulations - A Forward Look to 1992

Author(s): S R Walker & J P Griffin (Eds)
Publisher: MTP Press, Lancaster, England
Category: Regulatory

Issues of Concern in Clinical Development: The Growing Size of the Clinical Dossier

Author(s): C Hynes, J A N McAuslane & S R Walker (Eds)
Publisher: CMR International Workshop Review Reports 1998 - 1999
Category: Regulatory

Long-Term Animal Studies - Their Predictive Value for Man

Author(s): S R Walker & A D Dayan (Eds)
Publisher: MTP Press, Lancaster, England
Category: Toxicology

Medicines and Risk/Benefit Decisions

Author(s): S R Walker & A W Asscher (Eds)
Publisher: MTP Press, Lancaster, England
Category: R&D

Monitoring for Adverse Drug Reactions

Author(s): S R Walker & A Goldberg (Eds)
Publisher: MTP Press, Lancaster, England
Category: R&D

Pharmaceutical Patents. The Stimulus to Medicines Research

Author(s):
Publisher: CMR Publication
Category: R&D

Preparing for Successful Mutual Recognition in 1998 and Beyond

Author(s): S Russell, J A N McAuslane & S R Walker (Eds)
Publisher: CMR International Publication
Category: Regulatory

Quality of Life - Assessment and Application

Author(s): S R Walker & R M Rosser (Eds)
Publisher: MTP Press, Lancaster, England
Category: Quality of Life

Quality of Life - Assessment and Application (Japanese Edition)

Author(s): S R Walker & R M Rosser (Eds)
Publisher: The Japanese Society of Quality of Life Research, Kobe, Japan
Category: Quality of Life

Quality of Life Assessment - Key Issues in the 1990s

Author(s): S R Walker & R M Rosser (Eds)
Publisher: Kluwer Academic Publishers, The Netherlands
Category: Quality of Life

Safety Evaluation of Biotechnologically-derived Pharmaceuticals: Facilitating a Scientific Approach

Author(s): S A Griffiths & C E Lumley (Eds)
Publisher: Kluwer Academic Publishers, The Netherlands
Category: Toxicology

The Carcinogenicity Debate

Author(s): J A N McAuslane, C E Lumley & S R Walker (Eds)
Publisher: Quay Publishing, Lancaster, England
Category: Toxicology

The Effect of Corporate Culture on the Success of Research & Development

Author(s): S Dorabjee, C E Lumley & S R Walker (Eds)
Publisher: CMR International Publication
Category: Corporate Culture

The Pharmaceutical R & D Compendium: CMR International/Scrip's Guide to Trends in R & D

Author(s): G Findlay (Ed)
Publisher: CMR International/SCRIP Publication
Category: R&D

The Pharmaceutical R & D Compendium: CMR International/SCRIP's Guide to Trends in R & D (1997 Edition)

Author(s): C Spence (Ed)
Publisher: CMR International/SCRIP Publication
Category: R&D

The Relevance of Ethnic Factors in the Clinical Evaluation of Medicines

Author(s): S R Walker, C E Lumley & J A N McAuslane (Eds)
Publisher: Kluwer Academic Publishers, The Netherlands
Category: Regulatory

The Timing of Toxicological Studies to Support Clinical Trials

Author(s): C Parkinson, J A N McAuslane, C E Lumley & S R Walker (Eds)
Publisher: Kluwer Academic Publishers, The Netherlands
Category: Toxicology

Trends & Changes in Drug Research & Development

Author(s): B C L Walker & S R Walker (Eds)
Publisher: MTP Press, Lancaster, England
Category: R&D

Trends in Pharmaceutical R & D - The 1996 CMR Fact Book

Author(s): C E Lumley & S Dorabjee (Eds)
Publisher: CMR Publication
Category: R&D

A Study of Trends in Pharmaceutical Regulatory Approval Times for 9 Major Markets in the 1990's (Paper)

Year:
Subject: Regulatory Approval
Programme: Regulatory
Code:

Activities of the International Phamaceutical Industry in 1995

Year: 1997
Subject: Pipeline, Expenditure and Output
Programme: Pharmaceutical Investment and Output
Code: CMR97-70R

Activities of the International Pharmaceutical Industry in 1996: Pharmaceutical Investment and Output

Year: 1997
Subject: Pipeline, Expenditure and Output
Programme: Pharmaceutical Investment and Output
Code: CMR97-93R

Activities of the International Pharmaceutical Industry in 1997: Pharmaceutical Investment and Output

Year: 1998
Subject: Pipeline, Expenditure and Output
Programme: Pharmaceutical Investment and Output
Code: CMR98-104R2

Activities of the International Pharmaceutical Industry in1998: Pharmaceutical Investment and Output

Year: 1999
Subject: Pipeline, Expenditure and Output
Programme: Pharmaceutical Investment and Output
Code: CMR99-126R

Activities of the International Pharmaceutical Industry in1999: Pharmaceutical Investment and Output

Year: 2000
Subject: Pipeline, Expenditure and Output
Programme: Pharmaceutical Investment and Output
Code: CMR00-137R

Benchmarking for Efficient Drug Development

Year: 1997
Subject: Drug Development
Programme: General
Code: CMR97-80RA/B

Can the UK Automated Databases Provide Relevant Information for Health Economics Research

Year: 1997
Subject: Health Economics
Programme: General
Code: CMR97-97R

Challenging Issues for the Future of the Pharmaceutical Industry: Pharmaceutical Investment and Output in 2000

Year: 2001
Subject: Pipeline, Expenditure and Output
Programme: Pharmaceutical Investment and Output
Code: CMR01-153R

Current Strategies and Future Prospects in Pharmaceutical Outsourcing (Outsourcing Report)

Year:
Subject: Outsourcing
Programme: General
Code:

High Dose Selection for Carcinogenicity Studies of Pharmaceuticals Initiated in 1995

High Dose Selection for Carcinogenicity Studies: Implementation of the ICH Guideline During 1995 and 1996

Year: 1997
Subject: ICH
Programme: Regulatory
Code: CMR97-65R2

Improving the Regulatory Review Process: Assessing Performance and Setting Targets (Book)

Year:
Subject: Regulatory Review Process
Programme: Regulatory
Code:

Industry Experience with the New European Licensing Procedures: The First Twelve Months

Year: 1996
Subject: European Licensing Process
Programme: Regulatory
Code: CMR96-61R

Industry Insights: Current Experience with Mutual Recognition

International Pharamceutical R&D Expenditure and Sales 2001: Pharmaceutical Investment and Output Survey 2001: Data Report I

Year: 2002
Subject: R&D Expenditure and Sales
Programme: Pharmaceutical Investment and Output
Code: CMR02-171RA

Issues of Concern in Clinical Development: Characterising Recently Submitted Dossiers for New Active Substances

Year: 1999
Subject: Clinical
Programme: General
Code: CMR99-100R2

New Active Substance Activities 2001: Pharmaceutical Investment and Output Survey 2001: Data Report III

Year: 2002
Subject: New Active Substance Activities
Programme: Pharmaceutical Investment and Output
Code: CMR02-171RC

Non-clinical Safety Evaluation of Products of Biotechnology: Industry Strategies

Year: 1997
Subject: Safety
Programme: Regulatory
Code: CMR97-79R

Non-clinical Safety Testing of Products of Biotechnology: Issues of Concern

Year: 1995
Subject: Safety
Programme: Regulatory
Code: CMR95-63R

Performance of European Mutual Recognition Procedure: Submissions in the Transition Period January 1995 - November 1997

Year: 1997
Subject: European Mutual Recognition Procedure
Programme: Regulatory
Code: CMR97-61R2

Portfolio Management by Leading Pharmaceutical Companies: Current Approaches to Decision Making

Year: 1997
Subject: Portfolio Management
Programme: General
Code: CMR97-84R

Profile of the UK Pharmaceutical Industry 2000 to 2002

Year: 2001
Subject: General
Programme: UK R&D
Code: CMR01-161R

Profile of the UK Pharmaceutical Industry from 1998 to 2000 R&D Expenditure and Staffing

Year: 1999
Subject: R&D Expenditure and Staffing
Programme: UK R&D
Code: CMR99-125R

Profile of the UK Pharmaceutical Industry from 2000 to 2002: R&D Expenditure & Staffing

Year: 2001
Subject: R&D Expenditure and Staffing
Programme: UK R&D
Code: CMR01-163R

Profile of the UK Pharmaceutical Industry in 1997 and 1998

Year: 1999
Subject: General
Programme: UK R&D
Code: CMR99-98R

The CMR International 2004 R&D Factbook

Year: 2004
Subject: Pipeline, Success Rates, Investment, Sales, Discovery, CMC, Regulatory, Cycle Times, First Launches, Clinical
Programme: Industry Investment
Code: CMR04

The Effect of Corporate Culture on the Efficiency of Pharmaceutical R&D

Year: 1996
Subject: Organisations
Programme: General
Code: CMR96-55R1

The Global Ethical Development Pipeline 2001: Pharmaceutical Investment and Output Survey 2001: Data Report II

Year: 2002
Subject: Global Ethical Development Pipeline
Programme: Pharmaceutical Investment and Output
Code: CMR02-171RB

The Impact of ICH Efficacy Guidelines on the Clinical Development of Medicines

Year: 1997
Subject: ICH
Programme: Regulatory
Code: CMR97-57R

The Registration of Pharmaceuticals in Emerging Markets: Submission strategies and issues of concern in Asia, South America and Central and Eastern Europe

Year: 1999
Subject: Regulatory
Programme: Emerging Markets
Code: CMR99-108R

UK Pharmaceutical R&D Expenditure 1982-1996

Worldwide Pharmaceutical R&D Expenditure 1986-1996

Year: 1997
Subject: Expenditure
Programme: General
Code: CMR97-81R

An Elusive Element: Corporate Culture and its Effect on R&D Efficiency Average score

Table of contents: CMR96-55R1.pdf
Report: rd3.pdf

ASIA - R & D Briefing - pdf

Table of contents: CMR99-108R.pdf
Report: 24a.pdf

Asia Update: Key Issues In The Registration of Pharmaceuticals

Table of contents: CMR99-108R.pdf
Report: 32b.pdf

Assessing the Regulatory and Healthcare Environment in the Middle East

Report: rd35.pdf

Benchmarking for Efficient Drug Development

Report: randd30.pdf

Cause for Concern? Non-clinical Safety Testing of Biotechnology Products

Table of contents: CMR95-63R.pdf
Report: rd2.pdf

CENTRAL & EASTERN EUROPE - R & D Briefing

Report: 24b.pdf

CMR International News: April 2001 Issue

Report: april2001.pdf

CMR International News: Autumn 2000 Issue

Report: autumn2000.pdf

CMR International News: Spring 2000 Issue

Report: spring2000.pdf

CMR International News:< Spring 2002 Issue

Report: springnews2002.pdf

Describing Dossiers: Characterizing Clinical Dossiers for Global Registration- pdf

Table of contents: CMR99-100R2.pdf
Report: 25.pdf

Emerging Markets: Middle East Development and Submission Strategies for Pharmaceutical Registration

Table of contents: CMR99-108R.pdf
Report: 27.pdf

Emphasis on Economic Evaluation Relevance of Automated Databases

Table of contents: CMR97-97R.pdf
Report: rd13.pdf

Examining Endpoints: High Dose Selection for Carcinogenicity Studies

Table of contents: CMR97-65R2.pdf
Report: rd14.pdf

Focus on Pharma: UK performance in a global context

Table of contents: CMR99-109R.pdf
Report: brief23.pdf

Heading for Harmonization Impact of ICH Efficacy Guidelines

Table of contents: CMR97-57R.pdf
Report: rd12.pdf

Increasing Investment: A Further Perspective on Worldwide R&D Expenditure

Table of contents: CMR97-81R.pdf
Report: rd8.pdf

Japan in Focus: Strategies for Innovation and Global Drug Development - What Differentiates Japanese Pharma Companies from their Western Counterparts?

Report: japbriefing.pdf

Keys to Competition (2): Benefits from benchmarking drug development

Table of contents: CMR97-80RA.pdf
Report: rd17.pdf

Keys to Competition: Benchmarking for Efficient Drug Development Number of NMEs

Table of contents: CMR97-80RA.pdf
Report: rd6.pdf

Latin America- R & D Briefing

Report: 24c.pdf

Latin America Update: Key Issues In The Registration of Pharmaceuticals

Table of contents: CMR99-108R.pdf
Report: rd32a.pdf

Major Challenges for the Pharmaceutical Industry in the New Millennium

Table of contents: CMR00-137R_PIO_99_Contents.pdf
Report: CMR00-137R_PIO_99_Briefing.pdf

Mapping the Milestones: Similarities and Differences in Review Processes

Report: rd11.pdf

Market Access for New Medicines: Are companies changing their strategies?

Report: randd33.pdf

Outsourcing in Operation: Contracting out Pharmaceutical R&D

Report: rd20.pdf

Perfecting a Procedure: Evolution of mutual recognition during the transition period

Table of contents: CMR97-61R2.pdf
Report: rd16.pdf

Predictive Potential: Industry Strategies for Carcinogenicity Testing

Table of contents: CMR99-98R.pdf
Report: rd19.pdf

Prioritizing Projects: Current Issues in Portfolio Management

Table of contents: CMR97-84R.pdf
Report: rd7.pdf

Profile of Performance (2): Similarities and Differences in Regulatory Approval Times

Report: rd21.pdf

Profile of performance (3): Review times - is there still room for improvement?

Report: rd31.pdf

Profile of Performance Trends in regulatory approval times during the 1990s

Report: rd10.pdf

Reliance on Repetition: Company Strategies for Use of Foreign Clinical Data

Table of contents: CMR96-17R.pdf
Report: rd1.pdf

Strategic Statistics (2): Pharmaceutical investment and output in major markets

Table of contents: CMR98-104R2.pdf
Report: rd22.pdf

Strategic Statistics (3): Pharmaceutical Investment and Output in 1998

Table of contents: CMR99-126R.pdf
Report: 26.pdf

Strategic Statistics: Pharmaceutical Investment and Output in Major Markets

Table of contents: CMR97-93R.pdf
Report: rd15.pdf

Strategic Statistics: Profile of Pharmaceutical Investment and Output

Table of contents: CMR97-70R.pdf
Report: rd5.pdf

Testing the Transition Current Experience with the New European Licensing Procedures

Table of contents: CMR96-61R.pdf
Report: rd4.pdf

The changing role of non-clinical safety evaluation at the discovery/development interface: report of an industry discussion meeting

Report: randd29.pdf

The impact of the changing regulatory environment on review times

Report: r_d35.pdf

The impact of the ICH E5 Guideline on global drug development

Report: r_d36.pdf

Unifying Understanding: Safety Evaluation Strategies for Biotechnology Products

Table of contents: CMR97-79R.pdf
Report: rd18.pdf